U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C5H11NO2Se
Molecular Weight 196.11
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELENOMETHIONINE, DL-

SMILES

C[Se]CCC(N)C(O)=O

InChI

InChIKey=RJFAYQIBOAGBLC-UHFFFAOYSA-N
InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)

HIDE SMILES / InChI

Description

Selenomethionine, DL- is the racemic mixture of the D and L enantiomers of Selenomethionine, that used us animal’s dietary supplement. Selenomethionine, DL- was tolerated by chickens for fattening at up to 1.5 mg selenium supplemented/kg feed; Selenomethionine, DL- is therefore safe for chickens for fattening provided total dietary selenium does not exceed 0.5 mg/kg complete feed; this conclusion is extended to all animal species. Based on available toxicity studies and previous assessments of closely related compounds, it is concluded that selenium from Selenomethionine, DL- does not elicit any adverse effects not expected in a selenium compound. The use of Selenomethionine, DL- in animal nutrition is expected to result in a similar increase in selenium deposition in animal tissues/products as that resulting from other sources of Selenomethionine, DL- . To ensure consumer safety from consumption of food originating from animals fed Selenomethionine, DL-, dietary selenium supplementation from the additive should not exceed a maximum of 0.2 mg Se/kg complete feed. Although a Selenomethionine, DL- containing additive did not release any measurable dust, the additive is considered as a hazard by inhalation, which requires protection measures for users since the additive is not the subject of authorisation, and selenium is highly toxic. The additive is not an irritant to skin and eyes and is not a dermal sensitiser. The use of Selenomethionine, DL- in feed does not pose an additional risk to the environment, compared with other sources of selenium for which it will substitute, as long as the maximum authorised content in complete feed is not exceeded.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Animals dietary supplement 0.5 mg/kg complete feed.
Route of Administration: Oral
In Vitro Use Guide
Isolated chicken hepatocytes were seeded at a density of 2×10^3 /well in 96-well plates and cultured for 24 h prior to treatment with 0, 0.01, 0.02, 0.05, 0.1, 0.2, 0.4, 0.8, and 1.6 μg/mL AFB1 (Sigma-Aldrich). AFB1 solutions with different concentrations were prepared from a stock solution of 1 mg/mL AFB1 in dimethyl sulfoxide (DMSO). The stock solution was further diluted in culture media at the desired concentrations. The cells were then cultured at 37 °C in a 5% CO2 atmosphere for 24 h to reach 80% confluence and were then subjected to the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, USA). Absorbance was measured at 490 nm with a reference wavelength of 630 nm. Various concentrations of SeMet (0, 0.5, 1, 2, and 4 μM) were used to evaluate the protective effect of SeMet against AFB1 toxicity. Compared with the control group, the cell viability in the groups without AFB1 treatment was significant and was promoted by 12% and 13% when SeMet was supplemented at concentrations of 1 and 2 μM, respectively. The group that was treated with 0.05 μg/mL AFB1 had significantly reduced cell viability compared with the control group; however, these reductions were lower when 0.5, 1, 2, and 4 μM SeMet concentrations were supplemented